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httpContralateral carotid artery occlusion is not a
contraindication to carotid endarterectomy even
if shunts are not routinely used
Russell H. Samson, MD, Jennifer L. Cline, PhD, ARNP, David P. Showalter, MD, Michael R. Lepore, MD,
and Deepak G. Nair, MD, MS, MHA, Sarasota, Fla
Objective: Although controversial, carotid artery stenting (CAS) has been proposed as being safer than carotid endar-
terectomy (CEA) for patients with a contralateral internal carotid occlusion (CCO). Arguably, with a CCO, CAS should
be even safer than CEA if a shunt is not used. Accordingly, we reviewed our experience with 2183 CEAs performed
routinely without a shunt to evaluate the risk of CEA performed in a subset of 147 patients with a CCO.
Methods: Between 1988 and 2011, 147 CEAs (111 men [75%], 36 women [25%]) were routinely performed without
a shunt despite CCO. Of these patients, 76% were asymptomatic. CEAs were performed by seven surgeons using standard
techniques (not eversion), with patients under general anesthesia and blood pressure maintained at >130 mm Hg. All
patients received heparin (7500 U), and protamine reversal was routine. Median cross-clamp time was 20 minutes (range,
14-40 minutes).
Results: Three neurologic events occurred #30 days (2.0%). One transient ischemic attack (TIA) occurred immediately,
and one occurred on the ﬁrst postoperative day due to occlusion of the endarterectomy site. One patient sustained an
immediate stroke and died of a large computed tomography-documented atheroembolic shower.
Conclusions: Our data demonstrate the safety of CEA in the presence of a CCO, even when performed without a shunt. It
is unlikely that the stroke or delayed TIA could be attributed to nonshunting or CCO. Even if so, the stroke and death
rates would be lower than those previously reported for patients undergoing CEA in the presence of a CCO. This may be
due to short cross-clamp times, careful technique, general anesthesia, and blood pressure support. Given these low adverse
event rates, our experience refutes the assumption that patients with a CCO are at such a high risk for CEA that the only
alternative is CAS. (J Vasc Surg 2013;58:935-40.)The optimal intervention for severe ipsilateral carotid
stenosis with a contralateral carotid occlusion (CCO)
remains controversial. Revascularization of patients in the
presence of a CCO has been considered by some to be
high risk and associated with stroke rates as high as 5% to
10%.1,2 Such high stroke risks for carotid endarterectomy
(CEA) in the presence of CCO have been used to justify
carotid artery stenting (CAS) as an alternative to CEA.3
This bias against CEA is especially prevalent in the cardi-
ology literature.4 Others, however, have suggested that
the CEA risk in this setting is exaggerated and that CCO
may actually afford stroke protection during CEA.5
Adding to the confusion about the safety of CEA in the
presence of CCO is the controversy about whether shunts
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a shunt to evaluate the risk of CEA performed in a subset
of 147 patients with a CCO. Unique to this experience is
that our group routinely performs CEA on all-comers
without a shunt, even in the presence of a CCO. As
such, it is conceivable that the results of our nonshunt
technique would provide a strong argument for the risks
or safety of CEA in the presence of a CCO.
METHODS
Design. This is a nonrandomized but prospective
experience that includes 147 consecutive CEAs routinely
performed without a shunt despite CCO. The study period
was from May 1988 through November 2011. During the
same interval, 2036 CEAs were routinely performed
without a shunt but with a patent, although usually
stenosed, contralateral internal carotid artery. Demo-
graphic and surgical data were obtained on all patients at
the time of surgery and maintained in an AtriumMed elec-
tronic database (Atrium Medical Corp, Hudson, NH).
CEAs were performed by seven surgeons with various
experience ranging from junior partner to high-volume
operator. The procedures were performed at two local
hospitals. Indications for surgery were consistent with the
Society for Vascular Surgery (SVS) Updated Guidelines
for the Management of Extracranial Carotid Disease.6
Determination of the degree of ipsilateral stenosis and
conﬁrmation of CCO was obtained by duplex ultrasound935
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mography (CT) scan, or magnetic resonance angiography
(MRA) selectively, using the North American Symptomatic
Carotid Endarterectomy Trial (NASCET) criteria.7,8 Our
duplex criteria for determining the degree of ipsilateral
stenosis have been previously reported.9 Evaluation of the
completeness of the circle of Willis was not performed
because this would have required preoperative angiography,
MRA, high-resolution CT angiography, or transcranial
Doppler imaging in all patients. We believe that the infor-
mation gained would not have warranted the increased
expense or risk, especially if an invasive diagnostic tech-
nique was used. Further, we are not convinced that this in-
formation would change our procedure.
The database and medical record review were used to
determine the development of any new neurologic deﬁcit
or death #30 days of surgery. A new deﬁcit was deﬁned
as a change in motor, sensory, or cognitive performance.
A neurologist evaluated all patients who sustained a new
neurologic event, and relevant treatment was initiated.
Permanent craniofacial nerve injury, infection, and return
to the operating room for bleeding were also evaluated.
Myocardial infarction (MI), clinically evident or based on
enzyme results, was not studied for the purpose of this
report.
Surgical technique. Although CEA was performed by
seven surgeons and multiple anesthesiologists and nurse
anesthetists, an essentially uniform technique for CEA
was used throughout the 23-year period of this study.
Aspirin therapy was continued before CEA, but clopidogrel
was discontinued for at least 5 days before surgery unless
emergent surgery was required. All patients underwent
general anesthesia using a variety of anesthetic agents.
Halothane was used in the early procedures; sevoﬂurane
and desﬂurane have been used during the last 15 years.
Induction agents have included pentobarbital or propofol.
Normocapnia was preserved.
Systolic blood pressure was maintained at >130 mm
Hg during cross-clamp, using pharmacotherapy (phenyl-
ephrine) as necessary. We have no evidence to support
any speciﬁc blood pressure, but we assumed that the
patient should be at least normotensive and possibly mildly
hypertensive. However, by requesting that the blood pres-
sure always remain at >130 mm Hg, we have avoided
periods of hypotension, which may, or may not, be signif-
icant. We do not adjust the blood pressure to higher levels
for patients who come to the operating room hypertensive
but rather allow them to remain at that level unless
they have pressures >200 mm Hg, in which case it is low-
ered pharmacologically with medications selected by the
anesthesiologist.
A standardized dose of heparin (7500 U) was used in
all patients, regardless of weight. No method to determine
cerebral perfusion was used. Control of the internal carotid
artery (ICA) was achieved using a Kartchner clamp to
maximize distal exposure. Other vessels were occluded
using vessel loops or DeBakey clamps, if necessary. A
long arteriotomy was standard procedure to fully visualizethe end point in the ICA. Accordingly, tacking sutures
were seldom required.
Our technique includes meticulous removal of debris
from the vessel wall, back bleeding of the ICA, and ante-
grade perfusion of the external carotid artery upon comple-
tion of the arteriotomy closure to avoid ICA embolization.
The only change in technique occurred after 2001. Before
2001, Dacron patches (DuPont, Wilmington, Del) were
only used when the ICA measured <3 mm or with redo
procedures. Since 2001, patches have been used routinely.
Full protamine reversal was used in all patients. Postop-
erative blood tests to evaluate for myocardial ischemia were
not routinely performed.
Statistical methods. Statistical analysis was performed
using SPSS 20 software (SPSS Inc, Chicago, Ill). Categoric
data are expressed as numbers and percentages and contin-
uous variables as mean with standard deviation. Possible
signiﬁcant differences were analyzed between the group
means with the c2 test and Fisher exact test. A multiple
analysis of variance was used to see the main and interac-
tion effects of categoric variables on multiple dependent
interval variables. P < .05 was deﬁned as statistically signif-
icant. However, because of the small number of events (see
below), no statistically signiﬁcant variables could be
determined.
RESULTS
A total of 147 procedures were performed on 111 men
(75%) and 36 women (25%). Patients were a mean age of
72 years (range, 46-90 years); 29 patients (20%) were
aged >80 years. CEA was performed for asymptomatic
critical stenosis in 112 patients (76%) and for symptomatic
stenosis in 35 (24%). Preoperative symptoms included
transient ischemic attack (TIA) or amaurosis fugax in
22 patients (15%) and cerebrovascular accident (CVA) in
13 (9%). Median ipsilateral stenosis was 90% (range, 45%-
99%). The patient who underwent a CEA with a 45%
stenosis was symptomatic from a de novo carotid aneu-
rysm. Abnormal unilateral vertebral artery ﬂow was docu-
mented in 11 patients: retrograde in ﬁve (3.4%) and
absent in six (4.1%).
Risk factors were recorded prospectively. However,
data suitable for SVS classiﬁcation were available for only
91 patients. Of those, 16 (18%) were diabetic, 77 (85%)
were hypertensive, 78 (86%) were diagnosed with hyperlip-
idemia, 61 (67%) had a history of smoking, 66 (73%)
were taking antiplatelets, and 63 (69%) were taking statins.
All patients were prescribed antiplatelets and statins post-
operatively, unless contraindicated. Coronary artery disease
was present in 48 (53%) and chronic kidney disease in
12 (13%).
All procedures were performed in one of two local
hospitals, with 115 (76%) operations in one hospital and
32 (24%) in the other. Surgeons who did >20 CEAs yearly
performed 128 procedures (87%), and ﬁve surgeons with
less experience performed 19 procedures (13%).
General anesthesia was used routinely, and shunts were
never used. A patch was used in 82 procedures (66%), of
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(CCTs) averaged 20.4 minutes (standard deviation,
5.4 minutes; range, 14-40 minutes). CCT was signiﬁcantly
longer for less-experienced surgeons (P < .001) and when
patches were used (P < .005), but there were no associated
neurologic events. Additionally, because of the infrequent
occurrence of any morbidity or prolonged CCTs, the effect
of longer CCTs cannot be determined.
There were three neurologic events, no MI, and one
death. One patient sustained bihemispheric embolic
infarcts and died of the profound cerebral injury. As previ-
ously reported,9 we presume this was related to proximal
intraplaque hemorrhage and debris that showered after
removal of the proximal clamp, which had inadvertently
been applied in an area of severe plaque. The CT scan per-
formed immediately after the event demonstrated multiple
embolic infarcts throughout both cerebral cortices consis-
tent with an embolic shower and not watershed ischemia
that might have arisen from nonshunting anoxia.
The second patient who sustained an event awoke with
expressive aphasia that resolved after 18 hours. The endar-
terectomy site remained patent by duplex imaging, and
early CT revealed no evidence of infarct. The CCT was
15 minutes. Conceivably, an MRI could have shown an
infarct; however, by strict deﬁnition, a cerebral symptom
that resolves #24 hours in the presence of a negative CT
scan is a TIA and not a stroke.
A TIA occurred in the third patient on postoperative
day 1, manifested as slurred speech and a slight facial droop
that resolved in 20 minutes. The duplex scan was equiv-
ocal, so an arch aortogram and cerebral angiogram were
performed. This demonstrated bilateral ICA occlusions.
On the nonpatched endarterectomy side, there was an
abrupt occlusion of the proximal ICA 1 cm from its origin,
without reconstitution of the ICA. The vertebral and
basilar arteries were widely patent. Despite bilateral ICA
occlusion, the patient remained asymptomatic, and no
further intervention was performed. A CT scan was not
performed, and it is conceivable that it might have shown
an infarct. Thus, although clinically this event was a TIA,
one could suggest that it could have been classiﬁed as
a “minor” stroke if such a CT ﬁnding were present.
Accordingly, in the best-case scenario, the adverse
events were two TIAs (1.4%), one CVA (0.7%), and one
death (0.7%). However, if the last patient did indeed
sustain a CVA, the results would be one TIA (0.7%) and
two CVAs (1.4%). Regardless, the total central neurologic
event rate was 2.0%. Three cranial nerve injuries (2.0%)
were documented at 30 days: two injuries to the marginal
mandibular branch of the facial and one temporary hypo-
glossal. No patient required a return to the operating
room for bleeding or infection during the 30-day postop-
erative period.
DISCUSSION
Although controversial, some have suggested that CEA
in the presence of a CCO is associated with an increase in
adverse neurologic outcomes.10,11 Accordingly, supportersof CAS have proposed that it is a safer alternative than
CEA, ostensibly because procedural cerebral ischemic
time would be shorter.4,12,13 However, there are limited
data supporting the role of CAS in the presence of CCO.
The Stenting with Angioplasty and Protection in Patients
at High Risk for Endarterectomy (SAPPHIRE) study was
designed to evaluate the efﬁcacy of CAS in a high-risk
patient population. Patients required only one high-risk
variable for inclusion, one of which was CCO. Of those,
only 36 of the 167 patients (23.6%) in the CAS and 42
of the 167 patients (25.3%) in the CEA groups had
a CCO. The investigators reported noninferiority, but the
incidence of primary end points was exceptionally high
for the CAS and CEA groups, at 12.2% vs 21.1%, respec-
tively.14 Further, adverse event rates for the subset of
patients with CCO were not reported.
The ACCULINK for Revascularization of Carotids in
High-Risk Patients (ARCHeR) trial also addressed the
high-risk patient.15 CCO was present in 96 of the 581
patients (16.5%) enrolled. To qualify for inclusion, patients
had to have at least one other risk factor, including recent
coronary artery bypass grafting, two or more diseased coro-
nary arteries, unstable angina, or MI #30 days and in need
of revascularization. The 30-day stroke and death rate was
6.8% for the total population and was 11.6% for symptom-
atic patients and 5.4% for asymptomatic patients, which
remains well above the acceptable standards for revascular-
ization.15 Again, however, event rates for patients with
a CCO were not reported.
The Carotid RX Acculink/Accunet Post-approval Trial
to Uncover Unanticipated or Rare Events (CAPTURE)
registry included 288 patients (8.2%) with CCO of the
3500 enrolled.16 It also had a high primatry end point of
6.3% and has been criticized because it was not a random-
ized controlled trial. CCO was not independently associ-
ated with stroke in that study,16 suggesting that CAS
with CCO also had high event rates. The 6.3% that was
reported remains above the stroke rate reported in our
study population.
Another high-risk CAS registry was the Boston Scien-
tiﬁc EPI: A Carotid Stenting Trial for High-risk Surgical
Patients (BEACH) trial.17 The primary end point was
composite morbidity and mortality. Of the 480 patients
enrolled, 87 (18%) met inclusion criteria based on CCO.
The composite 1-year morbidity and mortality rates were
8.9%. The event rate in the setting of a CCO was 1.1%
(n ¼ 5).
In a recent evaluation of real-world data from the
Carotid Artery Revascularization and Endarterectomy
(CARE) registry, the primary composite end point of
death, nonfatal MI, and nonfatal stroke from CAS was
2.1% in patients with CCO and 2.6% in patients without
CCO.4 This would suggest that CAS in the presence of
CCO is noninferior to CAS in patients without a CCO.
The authors admitted that they did not directly compare
CEA with CAS in patients with CCO, yet they stated
that, “CEA is known to be associated with increased risk
in the presence of CCO.”4
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the assumption that CEA is unsafe in the presence of
a CCO. A literature review in 2004 by Rockman18 identi-
ﬁed 338 CEAs with CCO and found the presence of
a CCO did not signiﬁcantly increase the risk of periopera-
tive stroke and late outcomes. Dalainas et al13 studied
a similar number of CEAs with CCO and also found no
signiﬁcant difference in perioperative cardiac or neurologic
events. The da Silva et al1 evaluation of 700 patients under-
going CEA, of which 108 (15.4%) had a CCO, found no
signiﬁcant difference in stroke or death rates. Flanigan
et al19 investigated 207 SAPPHIRE-eligible high-risk
patients vs 235 normal-risk patients and found an overall
postoperative stroke rate of 1.4%, with no statistical differ-
ences between groups. Mozes et al20 evaluated 323
SAPPHIRE eligible high-risk patients, of which 66 patients
had CCO and also found no differences in stroke or death
rate.
In our series, the adverse neurologic event rate for
CEA in the setting of a CCO was 2.0% (n ¼ 3). We believe
only one neurologic event (0.7%) was directly related to the
CCO. That patient awoke with expressive aphasia that
resolved after 18 hours. The endarterectomy site remained
patent by duplex imaging, and early CT revealed no
evidence of infarct. Of interest, this was the only patient
with an adverse outcome who had a preoperative TIA.
Even if this patient were found to have suffered a stroke
by an MRI (which was not performed), this event would
have been classiﬁed at worst as a minor stroke and would
not have affected the overall neurologic complication
rate, which we have deﬁned by combining TIA and stroke.
The CCO was not responsible for the patient who died
of a stroke. That neurologic complication was related to
atherosclerotic debris that embolized on declamping. The
only other event, a TIA on postoperative day 1, was also
not related to performing the CEA in the presence of
a CCO. Rather, it was due to occlusion of the endarterec-
tomy site. Regardless of whether these other neurologic
events were, or were not, related to CCO, the overall
stroke and death rate of 2.0% is in keeping with previous
reports and is well within the recommended standards of
a 3% perioperative stroke and death rate.6,21,22
To further highlight the safety of CEA in the setting of
CCO, consider that our experience included routine non-
shunting in all patients. Many ﬁnd this technique is coun-
terintuitive for the preservation of cerebral perfusion,
especially in patients with a CCO. As such, the necessity
for shunting continues to polarize the vascular community.
Proponents for shunting argue that it is a safe and reliable
method for providing cerebral protection23,24 while allow-
ing an unhurried approach.15,16 However, shunts are not
necessarily benign and have been associated with dislodge-
ment of embolic material, air embolization, creation of
distal ﬂaps, and shunt occlusion. Outcomes with a shunt
are also operator-dependent. Surgeons who routinely place
shunts have better results than those who place shunts
selectively.25 Further, there are no reliable indicators to
select patients who should receive a shunt.26 Multiplestudies, including a Cochrane Review, have found no effect
of shunting vs nonshunting on stroke or death after CEA
with CCO.5,17,18,26,27 Some have hypothesized that with
most CCOs, the cerebral circulation develops adequate
collateral circulation to maintain perfusion to the brain.5
Despite these studies, it has been suggested that low
adverse event rates with routine nonshunting can only be
achieved by experienced surgeons who can perform an
expeditious CEA. After 2001, we used patches exclusively,
yet despite an increase in CCTs, no patient sustained a new
event. This is in keeping with the Rockman et al28 ﬁnding
that patching was associated with a signiﬁcant reduction in
perioperative stroke compared with primary closure. The
three adverse events in our patients occurred with primary
closures.
Further, studies have found no correlation between
CCTs and adverse neurologic complications, even with
average CCTs >45 minutes.29,30 In 1984, Littooy et al31
reported signiﬁcantly increased neurologic events only if
CCTs >60 minutes. Fortunately, perioperative manage-
ment and surgical techniques have improved considerably
since their report. Our median CCT was 20 minutes
(range, 14-40 minutes). Despite a signiﬁcant difference
between the surgeons’ CCTs, no correlation was found
between CCTs and neurologic events (P ¼ .40). Further,
our ﬁve less-experienced surgeons performed 13% of the
CEAs with CCO, with no adverse neurologic events
despite CCTs that averaged 26 minutes. Accordingly, we
believe our results are reproducible, provided the surgeon
has at least had formal training and experience with CEA.
Our results have evoked strong emotional reactions
regarding nonshunting, with some alluding to “pure
luck” that our results are good. On the basis of their expe-
rience with CEA under local anesthesia, some surgeons
may agree that shunts might not always be necessary but
ﬁnd it impossible to believe that shunts are not required
with a CCO. However, we routinely use general anesthesia
with pharmacologic blood pressure support. Further,
although for the purpose of this article we have chosen
to report only our experience with CEA in the presence
of CCO, our group has routinely not shunted 2036 “all-
comers” with patent contralateral ICAs, with a current
stroke rate of 1.18%.
Some limitations of our study warrant consideration.
All data were nonrandomized observational data collected
prospectively but analyzed retrospectively. Although
demographic and risk factor data were collected prospec-
tively, some information was missing. It could be argued
that our patient sample does not represent the general
population that requires CEA. However, the patients in
this series are similar to the CCO sample reported in
NASCET.10 Most were men aged >65 years, with severe
ipsilateral stenosis. Most had a history of tobacco use and
were hypertensive. Of interest, the current sample had
nearly double the rates of coronary artery disease and
hyperlipidemia, which likely reﬂects the historical timing
of the studies and evolving risk factor modiﬁcation and
diagnostics for coronary disease. Further, the patients
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More important, because our combined neurologic event
and death rate was so small, it is extremely unlikely that
the missing risk factors could have played any role in the
outcome and validity of our conclusions.
Another limitation could be that preoperative and
postoperative neurologic examinations by neurologists
were only requested postoperatively when the operating
surgeon noted a new event. Our protocol is to evaluate
the patient at discharge and at the 1-week, 1-month, and
6-month visits. Postoperative duplex evaluation of the
operated-on carotid artery is also performed at 1 month
and 6 months and then every 6 months or once yearly,
depending on the ultrasound ﬁndings. It is possible that
subtle neurologic events might not have been recorded.
However, our group took great pains to evaluate our
patients for even minor defects because of our interest in
our nonshunting technique and the awareness that this
technique could evoke controversy. For example, we classi-
ﬁed one patient who did not have a CCO as having sus-
tained a stroke when her carotid artery occluded after
surgery. Her only neurologic ﬁnding was persistent micro-
graphia and an inability to accurately place letters in the
down column of a crossword puzzle.
Our study also does not answer the question of
whether CEA can be performed safely under local anes-
thesia with CCO. Several large randomized clinical trials
and the General Anesthetic vs Local Anesthetic for carotid
surgery (GALA) trial did not ﬁnd signiﬁcantly different
event rates between general and local anesthesia.2,32 Our
technique involved a general anesthetic for all patients.
We do believe that the ultimate choice of anesthetic agent
should be at the discretion of the surgeon, but we think
that general anesthesia may confer advantages in patients
undergoing CEA with CCO. For example, blood pressure
can be easily controlled pharmacologically and oxygenation
well maintained throughout. Regardless, because none of
our procedures was performed under local anesthesia, we
cannot make any determinations about CEA without
a shunt using anything other than general anesthesia.
In addition, we could ﬁnd no evidence that CCT inﬂu-
enced outcome, so we cannot assume that very prolonged
CCTs are safe. Nevertheless, in our overall experience with
CEA, we have had a few CCTs that were >40 minutes,
without neurologic deﬁcits.
We also have not evaluated the effect of our proce-
dure on postoperative MI, because enzymatic tests for
MI were not routinely performed. However, recent eval-
uation of the Carotid Revascularization Endarterectomy
Versus Stenting Trial (CREST) data suggest that although
enzymatic-deﬁned MI can result in decreased long-term
survival, the increased risk of stroke with CAS also results
in increased long-term mortality.33
CONCLUSIONS
We have presented the largest series of CEA with
routine nonshunting in the setting of CCO. It is unique
in that we never shunt, as opposed to other studies wherenonshunting was based on predetermined criteria. Our
data suggest that the presence of a CCO does not place
the patient at increased risk for post-CEA neurologic
complications, provided that the procedure is performed
under general anesthesia. More importantly, our experi-
ence refutes the assumption that patients with CCO are
at such a high-risk for CEA that the only alternative is CAS.
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Circulation 2012;126:3054-61.Submitted Feb 22, 2013; accepted Apr 5, 2013.INVITED COMMENTARYWilliam C. Mackey, MD, Boston, MassIn this retrospective study, Samson and colleagues present
excellent results (2% neurologic event rate, 0.7% mortality, and
no clinically apparent myocardial infarctions) in 147 consecu-
tive contralateral carotid occlusion patients, who underwent
carotid endarterectomy (CEA) without shunting. They attri-
bute their success to the use of general anesthesia with careful
maintenance of systolic blood pressure above 130 mm Hg.
Their results add fuel to the controversies over neurologic
risk in contralateral occlusion patients and over the role of
shunting.
While provocative, the study is not deﬁnitive. It suffers from
the weaknesses inherent in retrospective analyses. The credibility
of the outcome data suffers from the absence of independent
routine pre- and post-CEA neurologic assessment and of a set
protocol for post-CEA brain imaging. It is almost certain that
there were more perioperative strokes than they report, though
these events were clinically silent or subtle. Furthermore, given
the authors’ use of phenylephrine-induced hypertension as
a means of cerebral protection, their failure to routinely monitor
postoperative cardiac enzymes represents a missed opportunity to
conﬁrm the safety of their protocol. Theoretically, at least, the
routine use of vasopressors will add to the hemodynamic stressof the surgery, thereby raising the risk of perioperative cardiac
morbidity.
Despite these shortcomings, this report conﬁrms four facts:
(1) Well-trained surgeons, working with detail-oriented anesthesi-
ologists and adhering to well-deﬁned management protocols, can
achieve excellent results with CEA even in putatively high-risk
patients. (2) CEA patients with contralateral occlusion are not
necessarily at high neurologic risk. (3) The argument that contra-
lateral occlusion represents an indication for carotid stenting is
specious. (4) Contralateral occlusion is not an absolute indication
for shunt placement during CEA.
The report does not establish the superiority of the authors’
practices, but it does establish their management protocol as one
acceptable approach to the management of CEA patients with
contralateral occlusion. Those who achieve excellent results in
this patient population with carotid stenting or with CEA with
shunting are not likely to be converted by these data, but now
have another standard against which to measure their outcomes.
Controversy over the risk associated with contralateral occlusion
and the role of shunting will continue. In the face of ongoing
controversy, surgeons will continue to adopt and report those
practices that provide optimal results for their patients.
